HLN
Haleon Plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.14
−0.11%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$8.91
From 52W high−18.90%
Volume18.68M
Market cap$40.17B
P/E (TTM)18.9x
P/S (TTM)2.7x
Div yield2.13%
Key dataNov 6, 2026
Open
$8.91
From 52W high
−18.90%
Volume
18.68M
Market cap
$40.17B
ValuationView details →
P/E (Fwd)
20.1x
EV/EBITDA
13.0x
P/E (TTM)
18.9x
RSI (14)
43.8
MomentumView details →
1D Return
−0.11%
YTD Return
−9.84%
SummaryUpdated Jun 1, 2026
Haleon plc (LSE:HLN) is a British multinational consumer healthcare company that was spun off from GlaxoSmithKline in July 2022, making it one of the world's largest standalone consumer healthcare companies. The company was formed through the demerger of GSK's consumer healthcare division, which had been built over decades through acquisitions and internal development. Headquartered in Brentford, United Kingdom, Haleon operates globally across North America, Europe, Middle East, Africa, Latin America, and Asia Pacific, managing a portfolio of well-established consumer health brands that reach millions of consumers daily.
Similar companies
Latest newsMore news →
JD Health International, Inc. said it would sign agreements at the JD Health International, Inc. with more than 20 global healthcare brands, including PFIZER INC, Merck KGaA, NOVO NORDISK A S, Takeda, Boehringer Ingelheim, Haleon plc, NOVARTIS AG and LEO PHARMA.2d agoHaleon plc reported third-quarter sales growth below expectations as cold and flu rates fell.9d ago